Theratechnologies Inc. – NASDAQ:THTX
Theratechnologies stock price today
$3.249
+1.45
+81.53%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Theratechnologies stock price monthly change
+24.31%
month
Theratechnologies stock price quarterly change
+24.31%
quarter
Theratechnologies stock price yearly change
+11.88%
year
Theratechnologies key metrics
Market Cap | 85.98M |
Enterprise value | 119.66M |
P/E | -1.65 |
EV/Sales | 1.49 |
EV/EBITDA | -4.30 |
Price/Sales | 0.95 |
Price/Book | -3.40 |
PEG ratio | 0.03 |
EPS | -0.18 |
Revenue | 82.40M |
EBITDA | 7.41M |
Income | -6.95M |
Revenue Q/Q | 25.42% |
Revenue Y/Y | 3.40% |
Profit margin | -59% |
Oper. margin | -49.85% |
Gross margin | 67.17% |
EBIT margin | -49.85% |
EBITDA margin | 9% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTheratechnologies stock price history
Theratechnologies stock forecast
Theratechnologies financial statements
| Aug 2023 | 20.85M | -746K | -3.58% |
|---|---|---|---|
| Nov 2023 | 23.45M | -2.75M | -11.75% |
| Feb 2024 | 16.08M | -4.43M | -27.58% |
| May 2024 | 22.01M | 986.70K | 4.48% |
| Aug 2025 | 24.5M | -1.14M | -4.69% |
|---|---|---|---|
| Aug 2025 | 25.55M | 1.37M | 5.4% |
| Aug 2025 | 24.5M | -860.93K | -3.51% |
| Nov 2025 | 26.85M | 2.75M | 10.27% |
Analysts Price target
Financials & Ratios estimates
| Aug 2023 | 56686000 | 98.39M | 173.57% |
|---|---|---|---|
| Nov 2023 | 77769000 | 98.63M | 126.84% |
| Feb 2024 | 71990966 | 96.55M | 134.13% |
| May 2024 | 70204909 | 93.40M | 133.05% |
| Aug 2023 | 5.32M | 558K | -7.91M |
|---|---|---|---|
| Nov 2023 | -4.10M | 142K | 23.09M |
| Feb 2024 | -1.69M | 132.67K | -272.27K |
| May 2024 | -463.42K | -135.15K | -472.60K |
Theratechnologies alternative data
| Aug 2023 | 144 |
|---|---|
| Sep 2023 | 144 |
| Oct 2023 | 144 |
| Nov 2023 | 144 |
| Dec 2023 | 144 |
| Jan 2024 | 144 |
| Feb 2024 | 144 |
| Mar 2024 | 103 |
| Apr 2024 | 103 |
| May 2024 | 103 |
| Jun 2024 | 103 |
| Jul 2024 | 103 |
Theratechnologies other data
6.75%
-19.23%
of THTX is owned by hedge funds
6.42M
-18.31M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 25 Jun 2021 Issue date: 21 Oct 2021 |
Application Filling date: 22 Mar 2019 Issue date: 24 Sep 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 10 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 26 Sep 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 12 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Paul Lévesque (1964) Pres, Chief Executive Officer & Director | $861,830 |
| Mr. Conor M. Walshe (1973) Gen. Mang. of Theratechnologies Europe Limited | $370,510 |
Dr. Christian Marsolais (1963) Senior Vice President & Chief Medical Officer | $357,280 |
Mr. Philippe Dubuc M.B.A., MBA (1967) Senior Vice President & Chief Financial Officer | $318,540 |
Mr. Jocelyn Lafond (1968) Vice President of Legal Affairs & Corporation Sec. | $281,340 |
-
What's the price of Theratechnologies stock today?
One share of Theratechnologies stock can currently be purchased for approximately $3.25.
-
When is Theratechnologies's next earnings date?
Unfortunately, Theratechnologies's (THTX) next earnings date is currently unknown.
-
Does Theratechnologies pay dividends?
No, Theratechnologies does not pay dividends.
-
How much money does Theratechnologies make?
Theratechnologies has a market capitalization of 85.98M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2.13% to 81.76M US dollars.
-
What is Theratechnologies's stock symbol?
Theratechnologies Inc. is traded on the NASDAQ under the ticker symbol "THTX".
-
What is Theratechnologies's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Theratechnologies?
Shares of Theratechnologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Theratechnologies's key executives?
Theratechnologies's management team includes the following people:
- Mr. Paul Lévesque Pres, Chief Executive Officer & Director(age: 61, pay: $861,830)
- Mr. Conor M. Walshe Gen. Mang. of Theratechnologies Europe Limited(age: 52, pay: $370,510)
- Dr. Christian Marsolais Senior Vice President & Chief Medical Officer(age: 62, pay: $357,280)
- Mr. Philippe Dubuc M.B.A., MBA Senior Vice President & Chief Financial Officer(age: 58, pay: $318,540)
- Mr. Jocelyn Lafond Vice President of Legal Affairs & Corporation Sec.(age: 57, pay: $281,340)
-
How many employees does Theratechnologies have?
As Jul 2024, Theratechnologies employs 103 workers.
-
When Theratechnologies went public?
Theratechnologies Inc. is publicly traded company for more then 16 years since IPO on 13 Feb 2009.
-
What is Theratechnologies's official website?
The official website for Theratechnologies is theratech.com.
-
Where are Theratechnologies's headquarters?
Theratechnologies is headquartered at 2015 Peel Street, Montreal, QC.
-
How can i contact Theratechnologies?
Theratechnologies's mailing address is 2015 Peel Street, Montreal, QC and company can be reached via phone at +1 514 336 7800.
Theratechnologies company profile:
Theratechnologies Inc.
theratech.comExchange:
NASDAQ
Full time employees:
103
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
2015 Peel Street
Montreal, QC H3A 1T8
Montreal, QC H3A 1T8
CIK: 0001512717
ISIN: CA88338H7040
CUSIP: 88338H100
